Hologic, Inc.

LSE:0J5Q Stock Report

Market Cap: US$18.3b

Hologic Valuation

Is 0J5Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0J5Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0J5Q ($78.69) is trading below our estimate of fair value ($130.47)

Significantly Below Fair Value: 0J5Q is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0J5Q?

Key metric: As 0J5Q is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0J5Q. This is calculated by dividing 0J5Q's market cap by their current earnings.
What is 0J5Q's PE Ratio?
PE Ratio26.1x
EarningsUS$701.50m
Market CapUS$18.26b

Price to Earnings Ratio vs Peers

How does 0J5Q's PE Ratio compare to its peers?

The above table shows the PE ratio for 0J5Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.9x
SN. Smith & Nephew
35.3x22.5%UK£8.6b
NIOX NIOX Group
23.7x17.1%UK£260.3m
EKF EKF Diagnostics Holdings
24.4xn/aUK£116.6m
CTEC ConvaTec Group
40.4x20.5%UK£4.9b
0J5Q Hologic
26.1x9.2%US$18.3b

Price-To-Earnings vs Peers: 0J5Q is good value based on its Price-To-Earnings Ratio (26.1x) compared to the peer average (30.9x).

Price to Earnings Ratio vs Industry

How does 0J5Q's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0J5Q 26.1xIndustry Avg. 29.7xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0J5Q is good value based on its Price-To-Earnings Ratio (26.1x) compared to the European Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 0J5Q's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0J5Q PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.1x
Fair PE Ratio32.7x

Price-To-Earnings vs Fair Ratio: 0J5Q is good value based on its Price-To-Earnings Ratio (26.1x) compared to the estimated Fair Price-To-Earnings Ratio (32.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0J5Q forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$78.69
US$87.22
+10.8%
7.2%US$96.00US$70.00n/a15
Nov ’25US$82.91
US$87.14
+5.1%
7.0%US$96.00US$70.00n/a16
Oct ’25US$80.61
US$86.93
+7.8%
7.9%US$96.00US$70.00n/a15
Sep ’25US$80.73
US$87.07
+7.8%
8.6%US$96.00US$70.00n/a15
Aug ’25US$82.76
US$86.50
+4.5%
8.6%US$96.00US$70.00n/a14
Jul ’25US$74.01
US$85.27
+15.2%
7.6%US$95.00US$70.00n/a15
Jun ’25US$72.99
US$85.14
+16.6%
7.8%US$95.00US$70.00n/a14
May ’25US$75.70
US$84.27
+11.3%
7.6%US$95.00US$70.00n/a15
Apr ’25US$77.83
US$82.67
+6.2%
7.6%US$95.00US$70.00n/a15
Mar ’25US$74.13
US$82.67
+11.5%
7.6%US$95.00US$70.00n/a15
Feb ’25US$74.35
US$81.39
+9.5%
7.5%US$95.00US$70.00n/a15
Jan ’25US$70.95
US$80.08
+12.9%
8.1%US$95.00US$70.00n/a16
Dec ’24US$71.26
US$79.83
+12.0%
8.5%US$95.00US$70.00n/a16
Nov ’24US$66.24
US$83.28
+25.7%
9.1%US$95.00US$70.00US$82.9115
Oct ’24US$69.93
US$88.33
+26.3%
8.1%US$95.00US$70.00US$80.6115
Sep ’24US$74.84
US$88.33
+18.0%
8.1%US$95.00US$70.00US$80.7315
Aug ’24US$76.35
US$88.80
+16.3%
8.1%US$98.00US$70.00US$82.7615
Jul ’24US$80.94
US$91.04
+12.5%
8.9%US$105.00US$70.00US$74.0114
Jun ’24US$78.69
US$91.04
+15.7%
8.9%US$105.00US$70.00US$72.9914
May ’24US$86.00
US$87.61
+1.9%
7.9%US$95.00US$70.00US$75.7014
Apr ’24US$80.57
US$86.04
+6.8%
8.5%US$95.00US$70.00US$77.8314
Mar ’24US$79.23
US$86.64
+9.4%
8.9%US$95.00US$70.00US$74.1314
Feb ’24US$81.52
US$82.36
+1.0%
8.6%US$91.00US$70.00US$74.3514
Jan ’24US$74.55
US$77.71
+4.2%
7.4%US$90.00US$70.00US$70.9514
Dec ’23US$76.88
US$77.25
+0.5%
7.3%US$90.00US$70.00US$71.2612
Nov ’23US$74.06
US$77.25
+4.3%
7.3%US$90.00US$70.00US$66.2412

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Guerbet

€339.2m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€27.00

7D

-9.8%

1Y

50.2%

Arjo

SEK 9.2b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 33.92

7D

-4.8%

1Y

-9.6%

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.06

7D

-6.1%

1Y

5.3%